CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW

Objective: The aim of this review is to assess patients with chronic myeloid leukemia with concomitant JA2 positive for - their characteristics - response to treatment Methodology: We searched the English literature (Google Scholar, PubMed, and SCOPUS) for studies, reviews, case series, and case rep...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Elrazi Ali, Elabbass Abdelmahmuod, Mohamed Yassin, Ashraf Ahmed, Maab Faisal
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/ee058b48de604e90ad6e353bb971957d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee058b48de604e90ad6e353bb971957d
record_format	dspace
spelling	oai:doaj.org-article:ee058b48de604e90ad6e353bb971957d2021-11-10T04:35:31ZCONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW2531-137910.1016/j.htct.2021.10.1027https://doaj.org/article/ee058b48de604e90ad6e353bb971957d2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011743https://doaj.org/toc/2531-1379Objective: The aim of this review is to assess patients with chronic myeloid leukemia with concomitant JA2 positive for - their characteristics - response to treatment Methodology: We searched the English literature (Google Scholar, PubMed, and SCOPUS) for studies, reviews, case series, and case reports of patients with chronic myeloid leukemia who had JAK2 mutation. Inclusion criteria: were the presence of JAK2 mutation in CML patients with BCR-ABL1 rearrangement and, secondly, age ≥18yrs. The search included all articles published up to 20th April 2021. Results: A total of 25 patients met our criteria of the search. Twenty-two patients were diagnosed in the chronic phase, 2 patients in the accelerated phase, and one patient transformed to the blast phase. More females n=16 and 10 males. The mean age at the time of diagnosis was 61.3 years. 9 patients had to be switch to second-line therapy. Age and gender distribution and the presence of splenomegaly or organomegaly are almost the same. Males were slightly more than females. Conclusion: It is difficult to conclude that multi-kinase inhibitors are superior to imatinib in treating CML with concomitant JAK2 mutation. But the result of the reported cases showed that multi-kinase inhibitors are more likely to be successful in achieving remission and loss of JAK2 mutation. However, it is difficult to generalize the result without further studies due to the few numbers of patients and the unusual association.Elrazi AliElabbass AbdelmahmuodMohamed YassinAshraf AhmedMaab FaisalElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S39- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Elrazi Ali Elabbass Abdelmahmuod Mohamed Yassin Ashraf Ahmed Maab Faisal CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
description	Objective: The aim of this review is to assess patients with chronic myeloid leukemia with concomitant JA2 positive for - their characteristics - response to treatment Methodology: We searched the English literature (Google Scholar, PubMed, and SCOPUS) for studies, reviews, case series, and case reports of patients with chronic myeloid leukemia who had JAK2 mutation. Inclusion criteria: were the presence of JAK2 mutation in CML patients with BCR-ABL1 rearrangement and, secondly, age ≥18yrs. The search included all articles published up to 20th April 2021. Results: A total of 25 patients met our criteria of the search. Twenty-two patients were diagnosed in the chronic phase, 2 patients in the accelerated phase, and one patient transformed to the blast phase. More females n=16 and 10 males. The mean age at the time of diagnosis was 61.3 years. 9 patients had to be switch to second-line therapy. Age and gender distribution and the presence of splenomegaly or organomegaly are almost the same. Males were slightly more than females. Conclusion: It is difficult to conclude that multi-kinase inhibitors are superior to imatinib in treating CML with concomitant JAK2 mutation. But the result of the reported cases showed that multi-kinase inhibitors are more likely to be successful in achieving remission and loss of JAK2 mutation. However, it is difficult to generalize the result without further studies due to the few numbers of patients and the unusual association.
format	article
author	Elrazi Ali Elabbass Abdelmahmuod Mohamed Yassin Ashraf Ahmed Maab Faisal
author_facet	Elrazi Ali Elabbass Abdelmahmuod Mohamed Yassin Ashraf Ahmed Maab Faisal
author_sort	Elrazi Ali
title	CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
title_short	CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
title_full	CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
title_fullStr	CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
title_full_unstemmed	CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW
title_sort	concomitant jak2 and bcr-abl1 in patients with chronic myeloid leukemia clinical impact and response to therapy: a systematic review
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/ee058b48de604e90ad6e353bb971957d
work_keys_str_mv	AT elraziali concomitantjak2andbcrabl1inpatientswithchronicmyeloidleukemiaclinicalimpactandresponsetotherapyasystematicreview AT elabbassabdelmahmuod concomitantjak2andbcrabl1inpatientswithchronicmyeloidleukemiaclinicalimpactandresponsetotherapyasystematicreview AT mohamedyassin concomitantjak2andbcrabl1inpatientswithchronicmyeloidleukemiaclinicalimpactandresponsetotherapyasystematicreview AT ashrafahmed concomitantjak2andbcrabl1inpatientswithchronicmyeloidleukemiaclinicalimpactandresponsetotherapyasystematicreview AT maabfaisal concomitantjak2andbcrabl1inpatientswithchronicmyeloidleukemiaclinicalimpactandresponsetotherapyasystematicreview
_version_	1718440611437084672

CONCOMITANT JAK2 AND BCR-ABL1 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CLINICAL IMPACT AND RESPONSE TO THERAPY: A SYSTEMATIC REVIEW

Ejemplares similares